|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
|
WO2006042237A2
(en)
|
2004-10-06 |
2006-04-20 |
Mayo Foundation For Medical Education And Research |
B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
|
|
ES2427646T5
(es)
*
|
2005-05-09 |
2017-08-22 |
Ono Pharmaceutical Co., Ltd. |
Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
|
|
US9387242B2
(en)
|
2005-12-02 |
2016-07-12 |
Icahn School Of Medicine At Mount Sinai |
Chimeric viruses presenting non-native surface proteins and uses thereof
|
|
PL2347775T3
(pl)
|
2005-12-13 |
2020-11-16 |
President And Fellows Of Harvard College |
Rusztowania do przeszczepiania komórek
|
|
WO2009029342A2
(en)
|
2007-07-13 |
2009-03-05 |
The Johns Hopkins University |
B7-dc variants
|
|
EP2328919A2
(en)
*
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
WO2010027423A2
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
|
HUE034832T2
(hu)
|
2008-12-09 |
2021-12-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
|
|
US20130017199A1
(en)
*
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
|
IL300733A
(en)
*
|
2010-03-05 |
2023-04-01 |
Univ Johns Hopkins |
Compositions and methods for antibodies and fusion proteins targeting immune modulation
|
|
WO2011133636A1
(en)
|
2010-04-20 |
2011-10-27 |
Cedars-Sinai Medical Center |
COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS
|
|
US9783578B2
(en)
|
2010-06-25 |
2017-10-10 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
WO2012018538A2
(en)
*
|
2010-07-26 |
2012-02-09 |
Schering Corporation |
Bioassays for determining pd-1 modulation
|
|
JP6104806B2
(ja)
|
2010-10-06 |
2017-03-29 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル
|
|
CN103261217B
(zh)
*
|
2010-11-11 |
2017-04-26 |
港大科桥有限公司 |
可溶性 pd‑1变体、融合构建体及其用途
|
|
JP6240063B2
(ja)
|
2011-04-28 |
2017-11-29 |
ザ ブロード インスティテュート， インコーポレイテッド |
ヒストンデアセチラーゼ阻害剤
|
|
CN102298053B
(zh)
*
|
2011-05-20 |
2014-01-29 |
中山大学肿瘤防治中心 |
原发性肝细胞肝癌术后复发风险评估的组合抗体试剂盒
|
|
CN103732238A
(zh)
*
|
2011-06-08 |
2014-04-16 |
奥瑞基尼探索技术有限公司 |
用于免疫调节的治疗性化合物
|
|
US20140234320A1
(en)
*
|
2011-06-20 |
2014-08-21 |
La Jolla Institute For Allergy And Immunology |
Modulators of 4-1bb and immune responses
|
|
WO2013003555A1
(en)
|
2011-06-28 |
2013-01-03 |
Whitehead Institute For Biomedical Research |
Using sortases to install click chemistry handles for protein ligation
|
|
CN103842030B
(zh)
*
|
2011-08-01 |
2018-07-31 |
霍夫曼-拉罗奇有限公司 |
使用pd-1轴结合拮抗剂和mek抑制剂治疗癌症的方法
|
|
GB201120527D0
(en)
*
|
2011-11-29 |
2012-01-11 |
Ucl Business Plc |
Method
|
|
AU2013211871B2
(en)
|
2012-01-25 |
2017-12-14 |
Board Of Regents, The University Of Texas System |
Biomarkers and combination therapies using oncolytic virus and immunomodulation
|
|
US9610250B2
(en)
|
2012-04-12 |
2017-04-04 |
Yale University |
Nanolipogel vehicles for controlled delivery of different pharmaceutical agents
|
|
LT2838515T
(lt)
|
2012-04-16 |
2020-03-10 |
President And Fellows Of Harvard College |
Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui
|
|
IN2014DN10991A
(ru)
|
2012-05-25 |
2015-09-25 |
Cellectis |
|
|
RU2689760C2
(ru)
|
2012-05-31 |
2019-05-30 |
Дженентек, Инк. |
Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
WO2014018979A1
(en)
|
2012-07-27 |
2014-01-30 |
The Broad Institute, Inc. |
Inhibitors of histone deacetylase
|
|
WO2014047350A1
(en)
*
|
2012-09-20 |
2014-03-27 |
Morningside Technology Ventures Ltd. |
Oncolytic virus encoding pd-1 binding agents and uses of the same
|
|
CA2886684C
(en)
*
|
2012-10-10 |
2023-09-19 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
|
WO2014121085A1
(en)
*
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Pd-l1 and pd-l2-based fusion proteins and uses thereof
|
|
US20150377891A1
(en)
*
|
2013-02-07 |
2015-12-31 |
(Institute National De La Santé Et De La Rechere Médicale) |
Methods for Predicting the Survival Time of Patients Suffering from Diffuse Large B-Cell Lymphomas
|
|
RU2708032C2
(ru)
|
2013-02-20 |
2019-12-03 |
Новартис Аг |
ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII
|
|
TW201446794A
(zh)
|
2013-02-20 |
2014-12-16 |
Novartis Ag |
利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
|
|
US9974845B2
(en)
|
2013-02-22 |
2018-05-22 |
Curevac Ag |
Combination of vaccination and inhibition of the PD-1 pathway
|
|
EP3292873B1
(en)
|
2013-02-22 |
2019-05-01 |
CureVac AG |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
US20160017011A1
(en)
*
|
2013-02-26 |
2016-01-21 |
Rongfu Wang |
Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
AU2014241843B2
(en)
|
2013-03-14 |
2019-05-02 |
Icahn School Of Medicine At Mount Sinai |
Newcastle disease viruses and uses thereof
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
MX2015014249A
(es)
|
2013-04-09 |
2016-06-02 |
Lixte Biotechnology Inc |
Formulaciones de oxabicicloheptanos y oxabicicloheptenos.
|
|
CN105339389B
(zh)
|
2013-05-02 |
2021-04-27 |
安奈普泰斯生物有限公司 |
针对程序性死亡-1(pd-1)的抗体
|
|
AU2014262469B2
(en)
|
2013-05-10 |
2019-11-14 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
|
WO2014183071A2
(en)
|
2013-05-10 |
2014-11-13 |
Whitehead Institute For Biomedical Research |
In vitro production of red blood cells with sortaggable proteins
|
|
US11311575B2
(en)
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
US9616129B2
(en)
|
2013-06-22 |
2017-04-11 |
Nitor Therapeutics |
Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
|
|
EP3659622A1
(en)
|
2013-08-08 |
2020-06-03 |
Cytune Pharma |
Combined pharmaceutical composition
|
|
EP3030575B1
(en)
|
2013-08-08 |
2018-07-11 |
Cytune Pharma |
Il-15 and il-15r-alpha sushi domain based modulokines
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
RS64268B1
(sr)
|
2013-09-20 |
2023-07-31 |
Bristol Myers Squibb Co |
Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
US10259875B2
(en)
|
2013-10-01 |
2019-04-16 |
Mayo Foundation For Medical Education And Research |
Methods for treating cancer in patients with elevated levels of BIM
|
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
|
WO2015066535A1
(en)
|
2013-11-01 |
2015-05-07 |
Yale University |
Modular particles for immunotherapy
|
|
WO2015073746A2
(en)
|
2013-11-13 |
2015-05-21 |
Whitehead Institute For Biomedical Research |
18f labeling of proteins using sortases
|
|
AU2014348657A1
(en)
|
2013-11-13 |
2016-05-19 |
Novartis Ag |
mTOR inhibitors for enhancing the immune response
|
|
CN105026428B
(zh)
|
2013-12-12 |
2018-01-16 |
上海恒瑞医药有限公司 |
PD‑l抗体、其抗原结合片段及其医药用途
|
|
KR20160099092A
(ko)
*
|
2013-12-17 |
2016-08-19 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
|
US10640569B2
(en)
|
2013-12-19 |
2020-05-05 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
US20170044268A1
(en)
*
|
2013-12-23 |
2017-02-16 |
OncoMed Pharmaceuticals |
Immunotherapy with Binding Agents
|
|
WO2015103602A1
(en)
*
|
2014-01-06 |
2015-07-09 |
The Trustees Of The University Of Pennsylvania |
Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
|
|
JP2017503503A
(ja)
*
|
2014-01-06 |
2017-02-02 |
エクスプレッション、パソロジー、インコーポレイテッド |
Ｐｄ−ｌ１に対するｓｒｍアッセイ
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
EP3102233A4
(en)
*
|
2014-02-05 |
2017-11-22 |
Cedars-Sinai Medical Center |
Methods and compositions for treating cancer and infectious diseases
|
|
KR102407019B1
(ko)
|
2014-02-27 |
2022-06-08 |
머크 샤프 앤드 돔 코포레이션 |
암의 치료를 위한 결합 방법
|
|
CN106255510A
(zh)
*
|
2014-03-05 |
2016-12-21 |
百时美施贵宝公司 |
使用抗pd‑1抗体与另一抗癌剂的组合治疗肾癌
|
|
KR20200029627A
(ko)
|
2014-03-12 |
2020-03-18 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
|
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
ES2754239T3
(es)
|
2014-03-12 |
2020-04-16 |
Curevac Ag |
Combinación de vacunación y agonistas de OX40
|
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
CN106103484B
(zh)
|
2014-03-14 |
2021-08-20 |
诺华股份有限公司 |
针对lag-3的抗体分子及其用途
|
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
|
PL3122745T3
(pl)
|
2014-03-24 |
2019-08-30 |
Novartis Ag |
Monobaktamowe związki organiczne do leczenia zakażeń bakteryjnych
|
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
|
IL280215B
(en)
|
2014-04-07 |
2022-07-01 |
Novartis Ag |
Cancer treatment using a chimeric receptor antigen (car) against cd19
|
|
JP7348708B2
(ja)
|
2014-04-30 |
2023-09-21 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
組み合わせワクチン装置および癌細胞を殺滅する方法
|
|
KR20170003692A
(ko)
|
2014-05-15 |
2017-01-09 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
|
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
|
PT3148579T
(pt)
|
2014-05-28 |
2021-03-11 |
Ludwig Inst For Cancer Res Ltd |
Anticorpos anti-gitr e métodos da sua utilização
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
MX2017000546A
(es)
|
2014-07-15 |
2017-03-08 |
Genentech Inc |
Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Ｃｄ３３キメラ抗原受容体を使用する癌の処置
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
WO2016014148A1
(en)
|
2014-07-23 |
2016-01-28 |
Mayo Foundation For Medical Education And Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
JP2017523213A
(ja)
|
2014-08-06 |
2017-08-17 |
ノバルティス アーゲー |
抗菌薬としてのキノロン誘導体
|
|
CN106687124B
(zh)
*
|
2014-08-07 |
2022-03-15 |
冈村春树 |
并用il-18与分子靶向抗体的癌治疗药
|
|
EP3177640B1
(en)
*
|
2014-08-08 |
2020-05-06 |
The Board of Trustees of the Leland Stanford Junior University |
High affinity pd-1 agents and methods of use
|
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
|
CN107108744B
(zh)
|
2014-08-19 |
2020-09-25 |
诺华股份有限公司 |
抗cd123嵌合抗原受体(car)用于癌症治疗
|
|
CN107206071A
(zh)
|
2014-09-13 |
2017-09-26 |
诺华股份有限公司 |
Alk抑制剂的联合疗法
|
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
|
US20170209574A1
(en)
|
2014-10-03 |
2017-07-27 |
Novartis Ag |
Combination therapies
|
|
US10053683B2
(en)
|
2014-10-03 |
2018-08-21 |
Whitehead Institute For Biomedical Research |
Intercellular labeling of ligand-receptor interactions
|
|
CN106973568B
(zh)
|
2014-10-08 |
2021-07-23 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
|
CA3003133C
(en)
*
|
2014-10-24 |
2020-09-15 |
StemImmune, Incorporated |
Combination immunotherapy approach for treatment of cancer
|
|
BR112017008914A2
(pt)
|
2014-10-29 |
2018-01-16 |
Five Prime Therapeutics, Inc. |
método para tratar câncer, composição e uso da composição
|
|
JP6887378B2
(ja)
*
|
2014-11-06 |
2021-06-16 |
バイオセラ，インク． |
腫瘍内微小環境に影響を与えるベータ−グルカン方法と組成物
|
|
CN113694193A
(zh)
|
2014-11-13 |
2021-11-26 |
约翰·霍普金斯大学 |
检查点阻断和微卫星不稳定性
|
|
JP6831783B2
(ja)
|
2014-11-14 |
2021-02-17 |
ノバルティス アーゲー |
抗体薬物コンジュゲート
|
|
BR112017011536A2
(pt)
*
|
2014-12-02 |
2018-02-27 |
Celgene Corp |
terapias de combinação
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
AU2015360903B2
(en)
|
2014-12-08 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
SG11201704053WA
(en)
|
2014-12-16 |
2017-06-29 |
Novartis Ag |
Isoxazole hydroxamic acid compounds as lpxc inhibitors
|
|
JP2018500332A
(ja)
*
|
2014-12-16 |
2018-01-11 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
中枢神経系新生物における免疫チェックポイント阻害剤の使用
|
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
|
CN105983097B
(zh)
*
|
2015-01-28 |
2021-06-08 |
华中科技大学同济医学院附属协和医院 |
一种抗肿瘤制剂及其制备方法
|
|
US11786457B2
(en)
*
|
2015-01-30 |
2023-10-17 |
President And Fellows Of Harvard College |
Peritumoral and intratumoral materials for cancer therapy
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
ES2882157T3
(es)
*
|
2015-02-13 |
2021-12-01 |
Sorrento Therapeutics Inc |
Productos terapéuticos de anticuerpos que se unen a CTLA4
|
|
NZ733854A
(en)
*
|
2015-02-26 |
2022-07-01 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
|
PE20171448A1
(es)
|
2015-03-10 |
2017-10-02 |
Aduro Biotech Inc |
Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
|
|
PE20171790A1
(es)
|
2015-03-23 |
2017-12-28 |
Bayer Pharma AG |
Anticuerpos anti-ceacam6 y sus usos
|
|
EP3280795B1
(en)
|
2015-04-07 |
2021-03-24 |
Novartis AG |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
EP3280464A4
(en)
|
2015-04-10 |
2018-09-26 |
President and Fellows of Harvard College |
Immune cell trapping devices and methods for making and using the same
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
ES2948133T3
(es)
|
2015-04-17 |
2023-08-31 |
Novartis Ag |
Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
|
|
SG11201708223QA
(en)
|
2015-04-17 |
2017-11-29 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
|
JP2018512856A
(ja)
|
2015-04-17 |
2018-05-24 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
調整可能な親和性を有する免疫調節タンパク質
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
KR20170140316A
(ko)
|
2015-04-28 |
2017-12-20 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료
|
|
JP2018514550A
(ja)
|
2015-04-28 |
2018-06-07 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
|
|
US20180155429A1
(en)
|
2015-05-28 |
2018-06-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
|
EP3303394B1
(en)
|
2015-05-29 |
2020-04-08 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
TW201709929A
(zh)
|
2015-06-12 |
2017-03-16 |
宏觀基因股份有限公司 |
治療癌症的聯合療法
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
KR20180040138A
(ko)
*
|
2015-07-13 |
2018-04-19 |
싸이톰스 테라퓨틱스, 인크. |
항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
|
|
RS61532B1
(sr)
|
2015-07-14 |
2021-04-29 |
Bristol Myers Squibb Co |
Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
|
|
CA2986705A1
(en)
|
2015-07-16 |
2017-01-19 |
Biokine Therapeutics Ltd. |
A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
|
|
MX2018000619A
(es)
|
2015-07-16 |
2019-03-06 |
Bioxcel Therapeutics Inc |
Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
|
|
JP7146632B2
(ja)
|
2015-07-21 |
2022-10-04 |
ノバルティス アーゲー |
免疫細胞の有効性および増大を改善する方法
|
|
EP4378957A2
(en)
|
2015-07-29 |
2024-06-05 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
JP6840127B2
(ja)
|
2015-07-29 |
2021-03-10 |
ノバルティス アーゲー |
がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
|
|
EP3964528A1
(en)
|
2015-07-29 |
2022-03-09 |
Novartis AG |
Combination therapies comprising antibody molecules to lag-3
|
|
KR20180030911A
(ko)
|
2015-07-29 |
2018-03-26 |
노파르티스 아게 |
Pd-1 길항제와 egfr 억제제의 조합물
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
DK3328419T3
(da)
|
2015-07-30 |
2021-10-11 |
Macrogenics Inc |
Pd-1-bindingsmolekyler og fremgangsmåder til anvendelse deraf
|
|
WO2017023753A1
(en)
|
2015-07-31 |
2017-02-09 |
University Of Florida Research Foundation, Inc. |
Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
|
|
BR112018000366A2
(pt)
|
2015-08-07 |
2018-09-11 |
Pieris Pharmaceuticals Gmbh |
polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão
|
|
KR102201147B1
(ko)
|
2015-08-11 |
2021-01-11 |
카리디 바이오테라퓨틱스, 인크. |
암 치료에 사용하기 위한 천연두 백신
|
|
CN108348521B
(zh)
|
2015-08-11 |
2021-12-03 |
诺华股份有限公司 |
用于治疗癌症的5-溴-2,6-二-(1h-吡唑-1-基)嘧啶-4-胺
|
|
CN116334205A
(zh)
|
2015-09-03 |
2023-06-27 |
诺华股份有限公司 |
预测细胞因子释放综合征的生物标志物
|
|
WO2017059397A1
(en)
|
2015-10-01 |
2017-04-06 |
Whitehead Institute For Biomedical Research |
Labeling of antibodies
|
|
SI3356411T1
(sl)
|
2015-10-02 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Bispecifična protitelesa, specifična za PD1 in TIM3
|
|
PE20181092A1
(es)
|
2015-10-02 |
2018-07-09 |
Hoffmann La Roche |
Anticuerpos anti-pd1 y metodos de uso
|
|
JP7320944B2
(ja)
|
2015-10-08 |
2023-08-04 |
マクロジェニクス，インコーポレーテッド |
Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子
|
|
EP3362074B1
(en)
|
2015-10-16 |
2023-08-09 |
President and Fellows of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
|
WO2017070110A1
(en)
|
2015-10-19 |
2017-04-27 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
|
CN108884139A
(zh)
|
2015-11-02 |
2018-11-23 |
戊瑞治疗有限公司 |
Cd80胞外域多肽及其在癌症治疗中的用途
|
|
WO2017077382A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
|
TW202408573A
(zh)
|
2015-11-18 |
2024-03-01 |
美商必治妥施貴寶公司 |
使用抗ｐｄ－１抗體與抗ｃｔｌａ－４抗體之組合以治療肺癌
|
|
SG10201913538VA
(en)
|
2015-11-23 |
2020-02-27 |
Five Prime Therapeutics Inc |
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
|
US11447557B2
(en)
|
2015-12-02 |
2022-09-20 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
US10590169B2
(en)
*
|
2015-12-09 |
2020-03-17 |
Virogin Biotech Canada Ltd |
Compositions and methods for inhibiting CD279 interactions
|
|
MY196756A
(en)
|
2015-12-14 |
2023-05-03 |
Macrogenics Inc |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子およびその使用
|
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
|
US20170198040A1
(en)
|
2015-12-18 |
2017-07-13 |
Novartis Ag |
ANTIBODIES TARGETING CD32b AND METHODS OF USE THEREOF
|
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
|
HUE063377T2
(hu)
|
2015-12-22 |
2024-01-28 |
Regeneron Pharma |
Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
|
|
ES2919552T3
(es)
|
2015-12-23 |
2022-07-27 |
Modernatx Inc |
Procedimientos de utilización de polinucleotidos codificadores de ligando ox40
|
|
US20190178888A1
(en)
|
2016-01-11 |
2019-06-13 |
Technion Research & Development Foundation Limited |
Methods of determining prognosis of sepsis and treating same
|
|
US10889643B2
(en)
|
2016-01-11 |
2021-01-12 |
Universität Zürich |
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
|
|
EP3411397A1
(en)
|
2016-02-05 |
2018-12-12 |
Orionis Biosciences NV |
Cd8 binding agents
|
|
CN109072197A
(zh)
|
2016-02-06 |
2018-12-21 |
哈佛学院校长同事会 |
重塑造血巢以重建免疫
|
|
CN109071447B
(zh)
|
2016-02-19 |
2022-04-22 |
诺华股份有限公司 |
四环吡啶酮化合物作为抗病毒剂
|
|
WO2017151517A1
(en)
|
2016-02-29 |
2017-09-08 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
|
SG11201807489PA
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
US20170252417A1
(en)
|
2016-03-07 |
2017-09-07 |
Massachusetts Institute Of Technology |
Protein-chaperoned t-cell vaccines
|
|
EP3426271A4
(en)
|
2016-03-10 |
2019-10-16 |
Cold Genesys, Inc. |
METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY POLYTHERAPY
|
|
JP2019512271A
(ja)
|
2016-03-21 |
2019-05-16 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用
|
|
EP3433257B1
(en)
|
2016-03-24 |
2023-10-11 |
Novartis AG |
Alkynyl nucleoside analogs as inhibitors of human rhinovirus
|
|
US11209441B2
(en)
|
2016-04-05 |
2021-12-28 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis
|
|
CA3020830A1
(en)
|
2016-04-13 |
2017-10-19 |
Vivia Biotech, S.L |
Ex vivo bite.rtm. activated t cells
|
|
MA43552A
(fr)
|
2016-04-15 |
2018-11-07 |
Alpine Immune Sciences Inc |
Protéines immunomodulatrices à variants de cd80 et leurs utilisations
|
|
US11753463B2
(en)
|
2016-05-13 |
2023-09-12 |
Orionis Biosciences BV |
Therapeutic targeting of non-cellular structures
|
|
TW202408578A
(zh)
|
2016-05-13 |
2024-03-01 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
CA3023883A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
|
RS63912B1
(sr)
|
2016-05-18 |
2023-02-28 |
Modernatx Inc |
Polinukleotidi koji kodiraju interleukin-12 (il12) i njihove upotrebe
|
|
CA3024917A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Combinations of mrnas encoding immune modulating polypeptides and uses thereof
|
|
AU2017268399B2
(en)
|
2016-05-18 |
2023-01-12 |
Modernatx, Inc. |
mRNA combination therapy for the treatment of cancer
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
IL263110B
(en)
|
2016-05-20 |
2022-07-01 |
Lilly Co Eli |
Combined treatment of notch and pd-1 or pd-l1 inhibitors
|
|
SG11201810023QA
(en)
|
2016-05-27 |
2018-12-28 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
|
US11083790B2
(en)
|
2016-06-02 |
2021-08-10 |
Bristol-Myers Squibb Company |
Treatment of Hodgkin lymphoma using an anti-PD-1 antibody
|
|
EP4248989A3
(en)
|
2016-06-02 |
2023-12-27 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
|
|
CN109476753A
(zh)
|
2016-06-03 |
2019-03-15 |
百时美施贵宝公司 |
用于治疗肿瘤的方法的抗-pd-1抗体
|
|
JP2019517512A
(ja)
|
2016-06-03 |
2019-06-24 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用
|
|
KR20190015407A
(ko)
|
2016-06-03 |
2019-02-13 |
브리스톨-마이어스 스큅 컴퍼니 |
재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
|
|
PL3468957T3
(pl)
|
2016-06-14 |
2021-01-25 |
Novartis Ag |
Krystaliczna postać (r)-4-(5-(cyklopropyloetynylo)izoksa-zol-3- ilo)- n-hydroksy-2-metylo-2-(metylosulfonylo)butano-amidu jako środek przeciwbakteryjny
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
CN109640999A
(zh)
|
2016-06-24 |
2019-04-16 |
无限药品股份有限公司 |
组合疗法
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
WO2018013797A1
(en)
|
2016-07-13 |
2018-01-18 |
President And Fellows Of Harvard College |
Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
|
|
CN116769050A
(zh)
|
2016-07-20 |
2023-09-19 |
犹他大学研究基金会 |
Cd229 car t细胞及其使用方法
|
|
SG11201900677SA
(en)
*
|
2016-07-28 |
2019-02-27 |
Novartis Ag |
Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
|
|
JP2019525934A
(ja)
|
2016-07-29 |
2019-09-12 |
イーライ リリー アンド カンパニー |
癌の治療に使用するためのメレスチニブおよび抗ｐｄ−ｌ１または抗ｐｄ−１阻害剤を用いた組み合わせ治療
|
|
JP2019527236A
(ja)
|
2016-08-01 |
2019-09-26 |
モレキュラー テンプレーツ，インコーポレイティド |
癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
|
|
RU2757394C2
(ru)
|
2016-08-03 |
2021-10-14 |
Нексткьюр, Инк. |
Композиции и способы для модуляции передачи сигнала lair
|
|
JP2019528689A
(ja)
*
|
2016-08-11 |
2019-10-17 |
ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ |
免疫調節化合物
|
|
EP3505183B1
(en)
*
|
2016-08-26 |
2022-03-30 |
Tetsuji Okuno |
Microvascular blood flow decreasing agent and use thereof
|
|
WO2018047109A1
(en)
|
2016-09-09 |
2018-03-15 |
Novartis Ag |
Polycyclic pyridone compounds as antivirals
|
|
AU2017322501A1
(en)
|
2016-09-09 |
2019-03-28 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Combination of an anti-CD20 antibody, PI3 kinase-delta inhibitor, and anti-PD-1 or anti-PD-L1 antibody for treating hematological cancers
|
|
WO2018048975A1
(en)
|
2016-09-09 |
2018-03-15 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
|
PL3512547T3
(pl)
*
|
2016-09-14 |
2021-03-08 |
Abbvie Biotherapeutics Inc. |
Przeciwciała anty-pd-1
|
|
EP4360714A2
(en)
|
2016-09-21 |
2024-05-01 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
|
AU2017332161A1
(en)
|
2016-09-21 |
2019-04-04 |
The United States Government As Represented By The Department Of Veterans Affairs |
Chimeric antigen receptor (car) that targets chemokine receptor CCR4 and its use
|
|
DK3515478T3
(da)
|
2016-09-21 |
2024-05-21 |
Nextcure Inc |
Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
|
|
CN118005799A
(zh)
|
2016-09-23 |
2024-05-10 |
马伦戈治疗公司 |
包含λ轻链和κ轻链的多特异性抗体分子
|
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
|
TW202340473A
(zh)
|
2016-10-07 |
2023-10-16 |
瑞士商諾華公司 |
利用嵌合抗原受體之癌症治療
|
|
KR20230133934A
(ko)
|
2016-10-11 |
2023-09-19 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
|
TW201819380A
(zh)
|
2016-10-18 |
2018-06-01 |
瑞士商諾華公司 |
作為抗病毒劑之稠合四環吡啶酮化合物
|
|
JP7204643B2
(ja)
|
2016-10-24 |
2023-01-16 |
オリオニス バイオサイエンシズ ビーブイ |
標的変異インターフェロン－ガンマおよびその使用
|
|
US20200024324A1
(en)
|
2016-10-27 |
2020-01-23 |
Io Biotech Aps |
New pdl2 compounds
|
|
MX2019005117A
(es)
|
2016-11-01 |
2019-10-21 |
Anaptysbio Inc |
Anticuerpos dirigidos contra la muerte programada 1 (pd-1).
|
|
CA3039992A1
(en)
|
2016-11-02 |
2018-05-11 |
Jounce Therapeutics, Inc. |
Antibodies to pd-1 and uses thereof
|
|
JP7267914B2
(ja)
|
2016-11-02 |
2023-05-02 |
エンクマフ エスアーエールエル |
Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
|
|
TW201825119A
(zh)
|
2016-11-30 |
2018-07-16 |
日商協和醱酵麒麟有限公司 |
使用抗ccr4抗體及抗pd-1抗體治療癌症之方法
|
|
BR112019011025A2
(pt)
|
2016-12-03 |
2019-10-08 |
Juno Therapeutics Inc |
métodos para modulação de células t car
|
|
AU2017373944B2
(en)
|
2016-12-07 |
2022-02-03 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
CN110300599A
(zh)
|
2016-12-07 |
2019-10-01 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
WO2018129497A1
(en)
|
2017-01-09 |
2018-07-12 |
Bioxcel Therapeutics, Inc. |
Predictive and diagnostic methods for prostate cancer
|
|
KR102606252B1
(ko)
|
2017-01-09 |
2023-11-23 |
테사로, 인코포레이티드 |
항-pd-1 항체로 암을 치료하는 방법
|
|
JP2020503883A
(ja)
|
2017-01-13 |
2020-02-06 |
アジェナス インコーポレイテッド |
Ｎｙ−ｅｓｏ−１に結合するｔ細胞受容体およびその使用方法
|
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
|
TWI788321B
(zh)
|
2017-01-20 |
2023-01-01 |
美商健臻公司 |
骨靶向抗體
|
|
EP3570870A1
(en)
|
2017-01-20 |
2019-11-27 |
Novartis AG |
Combination therapy for the treatment of cancer
|
|
TWI787230B
(zh)
|
2017-01-20 |
2022-12-21 |
法商賽諾菲公司 |
抗ＴＧＦ-β抗體及其用途
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
WO2018144999A1
(en)
|
2017-02-06 |
2018-08-09 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
|
CN110546160A
(zh)
|
2017-02-06 |
2019-12-06 |
奥里尼斯生物科学公司 |
靶向嵌合蛋白及其用途
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
KR20240011262A
(ko)
|
2017-02-21 |
2024-01-25 |
리제너론 파아마슈티컬스, 인크. |
폐암의 치료를 위한 항-pd-1 항체
|
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
|
PE20200735A1
(es)
|
2017-02-28 |
2020-07-23 |
Sanofi Sa |
Arn terapeutico
|
|
WO2018163051A1
(en)
|
2017-03-06 |
2018-09-13 |
Novartis Ag |
Methods of treatment of cancer with reduced ubb expression
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
US20200150125A1
(en)
|
2017-03-12 |
2020-05-14 |
Yeda Research And Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
|
EP3596114A2
(en)
|
2017-03-16 |
2020-01-22 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
CA3057687A1
(en)
|
2017-03-31 |
2018-10-04 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
AU2018247765B2
(en)
|
2017-04-03 |
2023-11-23 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of an Anti-PD-1 antibody with a mutant IL-2 or with IL-15
|
|
IL268527B2
(en)
|
2017-04-05 |
2024-03-01 |
Hoffmann La Roche |
Bispecific antibodies bind to PD1 and LAG3 specifically
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
MX2019012223A
(es)
|
2017-04-13 |
2019-12-09 |
Agenus Inc |
Anticuerpos anti-cd137 y metodos de uso de los mismos.
|
|
WO2018195283A1
(en)
|
2017-04-19 |
2018-10-25 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
CA3057748A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
|
CN110582303A
(zh)
|
2017-04-20 |
2019-12-17 |
Adc治疗有限公司 |
使用抗cd25抗体-药物缀合物的组合疗法
|
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
CA3059769A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
MX2019012849A
(es)
|
2017-04-28 |
2019-11-28 |
Five Prime Therapeutics Inc |
Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
EP3618863B1
(en)
|
2017-05-01 |
2023-07-26 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
|
UY37718A
(es)
|
2017-05-05 |
2018-11-30 |
Novartis Ag |
2-quinolinonas triciclicas como agentes antibacteriales
|
|
AU2018265856B2
(en)
|
2017-05-12 |
2023-04-27 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
JP7274426B2
(ja)
|
2017-05-16 |
2023-05-16 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗ｇｉｔｒアゴニスト抗体での癌の処置
|
|
EP3625246A1
(en)
|
2017-05-18 |
2020-03-25 |
ModernaTX, Inc. |
Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
|
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
|
MX2019014023A
(es)
|
2017-05-24 |
2020-02-17 |
Novartis Ag |
Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
MX2019012076A
(es)
|
2017-05-30 |
2019-12-09 |
Bristol Myers Squibb Co |
Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
|
|
EP4306542A3
(en)
|
2017-05-30 |
2024-04-17 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
|
CA3060989A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
|
US20210246227A1
(en)
|
2017-05-31 |
2021-08-12 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
KR20200024158A
(ko)
|
2017-05-31 |
2020-03-06 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
|
WO2018223002A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd 123 cd3
|
|
US11559504B2
(en)
*
|
2017-06-02 |
2023-01-24 |
The Penn State Research Foundation |
Ceramide nanoliposomes, compositions and methods of using for immunotherapy
|
|
AU2018275894A1
(en)
|
2017-06-02 |
2019-12-12 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
JP2020522562A
(ja)
|
2017-06-06 |
2020-07-30 |
ストキューブ アンド シーオー．， インコーポレイテッド |
Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
|
|
WO2018229222A1
(en)
|
2017-06-14 |
2018-12-20 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-cd19 adc
|
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
WO2018237157A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
|
|
JP2020526194A
(ja)
|
2017-06-29 |
2020-08-31 |
ジュノー セラピューティクス インコーポレイテッド |
免疫療法薬と関連する毒性を評価するためのマウスモデル
|
|
US11285149B2
(en)
|
2017-07-28 |
2022-03-29 |
Dana-Farber Cancer Institute, Inc. |
Enhanced immunotherapy of cancer using targeted transcriptional modulators
|
|
WO2019023624A1
(en)
|
2017-07-28 |
2019-01-31 |
Bristol-Myers Squibb Company |
PREDICTIVE PERIPHERAL BLOOD BIOMARKER FOR INHIBITORS OF CONTROL POINTS
|
|
WO2019036438A1
(en)
*
|
2017-08-14 |
2019-02-21 |
Phosphorex, Inc. |
ADENOSINE RECEPTOR ANTAGONIST MICROPARTICLE FORMULATIONS FOR THE TREATMENT OF CANCER
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
WO2019035985A1
(en)
|
2017-08-18 |
2019-02-21 |
Tragara Pharmaceuticals, Inc. |
POLYMORPHIC FORM OF TG02
|
|
WO2019046321A1
(en)
|
2017-08-28 |
2019-03-07 |
Bristol-Myers Squibb Company |
TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS
|
|
CA3073055A1
(en)
|
2017-09-04 |
2019-03-07 |
Agenus Inc. |
T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
|
|
AU2018330180A1
(en)
|
2017-09-07 |
2020-03-19 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
|
SG11202003341UA
(en)
|
2017-10-13 |
2020-05-28 |
Harpoon Therapeutics Inc |
B cell maturation antigen binding proteins
|
|
CN109662966A
(zh)
*
|
2017-10-16 |
2019-04-23 |
北京莱科金基因科技有限责任公司 |
伊曲茶碱在制备用于肿瘤治疗的药物中的用途
|
|
WO2019077062A1
(en)
|
2017-10-18 |
2019-04-25 |
Vivia Biotech, S.L. |
C-CELLS ACTIVATED BY BIT
|
|
US20210132042A1
(en)
|
2017-11-01 |
2021-05-06 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
MX2020004243A
(es)
|
2017-11-01 |
2020-09-25 |
Juno Therapeutics Inc |
Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
|
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
|
CA3082409A1
(en)
|
2017-11-17 |
2019-05-23 |
Merck Sharp & Dohme Corp. |
Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
|
|
US20210079015A1
(en)
|
2017-11-17 |
2021-03-18 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
|
CA3083949A1
(en)
|
2017-11-30 |
2020-06-06 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
WO2019113464A1
(en)
|
2017-12-08 |
2019-06-13 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
US11946094B2
(en)
|
2017-12-10 |
2024-04-02 |
Augusta University Research Institute, Inc. |
Combination therapies and methods of use thereof
|
|
CN112204048A
(zh)
|
2017-12-15 |
2021-01-08 |
朱诺治疗学股份有限公司 |
抗cct5结合分子及其使用方法
|
|
JP2021507906A
(ja)
|
2017-12-20 |
2021-02-25 |
ノバルティス アーゲー |
抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
|
|
US11324774B2
(en)
|
2018-01-05 |
2022-05-10 |
Augusta University Research Institute, Inc. |
Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
|
|
EP3737696A1
(en)
|
2018-01-12 |
2020-11-18 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
JP2021510733A
(ja)
|
2018-01-12 |
2021-04-30 |
ケーディーエーシー セラピューティクス，インコーポレーテッドＫｄａｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ
|
|
US20210038559A1
(en)
|
2018-01-22 |
2021-02-11 |
Thomas Richard Gadek |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
|
EP3743447B1
(en)
|
2018-01-23 |
2024-03-27 |
Nextcure, Inc. |
B7-h4 antibodies and methods of use thereof
|
|
US20210069246A1
(en)
|
2018-01-31 |
2021-03-11 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
|
WO2019149716A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
US20200405806A1
(en)
|
2018-02-08 |
2020-12-31 |
Bristol-Myers Squibb Company |
Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
|
|
EP3759110A1
(en)
|
2018-02-28 |
2021-01-06 |
Novartis AG |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
|
KR102594028B1
(ko)
|
2018-03-07 |
2023-10-24 |
화이자 인코포레이티드 |
항-pd-1 항체 조성물
|
|
CA3093742A1
(en)
|
2018-03-12 |
2019-09-19 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
JP7037218B2
(ja)
|
2018-03-14 |
2022-03-16 |
サーフィス オンコロジー インコーポレイテッド |
Ｃｄ３９と結合する抗体及びその使用
|
|
US20210361734A1
(en)
*
|
2018-03-19 |
2021-11-25 |
9 Meters Biopharma, Inc. |
Compositions and methods for potentiating immune checkpoint inhibitor therapy
|
|
WO2019195658A1
(en)
|
2018-04-05 |
2019-10-10 |
Dana-Farber Cancer Institute, Inc. |
Sting levels as a biomarker for cancer immunotherapy
|
|
CA3096674A1
(en)
|
2018-04-12 |
2019-10-17 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
|
CN114028568A
(zh)
|
2018-04-16 |
2022-02-11 |
上海岸阔医药科技有限公司 |
预防或治疗肿瘤疗法副作用的方法
|
|
WO2019204462A2
(en)
|
2018-04-17 |
2019-10-24 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
|
CN112105645A
(zh)
|
2018-04-18 |
2020-12-18 |
Xencor股份有限公司 |
Il-15/il-15ra异二聚体fc融合蛋白及其用途
|
|
EP3781599A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
MA52363A
(fr)
|
2018-04-26 |
2021-03-03 |
Agenus Inc |
Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
CN113286616A
(zh)
|
2018-05-23 |
2021-08-20 |
Adc治疗有限公司 |
分子佐剂
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
US11932681B2
(en)
|
2018-05-31 |
2024-03-19 |
Novartis Ag |
Hepatitis B antibodies
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
JP2021525769A
(ja)
|
2018-06-01 |
2021-09-27 |
ノバルティス アーゲー |
Ｃｄ１２３及びｃｄ３に結合する二重特異性抗体の投与
|
|
WO2019234576A1
(en)
|
2018-06-03 |
2019-12-12 |
Lamkap Bio Beta Ltd. |
Bispecific antibodies against ceacam5 and cd47
|
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
TW202005985A
(zh)
|
2018-06-21 |
2020-02-01 |
美商再生元醫藥公司 |
用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法
|
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
WO2020012334A1
(en)
|
2018-07-10 |
2020-01-16 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020014583A1
(en)
|
2018-07-13 |
2020-01-16 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
|
|
US20210238287A1
(en)
|
2018-07-26 |
2021-08-05 |
Bristol-Myers Squibb Company |
LAG-3 Combination Therapy for the Treatment of Cancer
|
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
|
KR20210052468A
(ko)
|
2018-08-27 |
2021-05-10 |
피어이스 파마슈티컬즈 게엠베하 |
Cd137/her2 이중특이적 제제 및 pd-1 축 억제제를 포함하는 조합물 치료요법 및 이의 용도
|
|
CN109053895B
(zh)
*
|
2018-08-30 |
2020-06-09 |
中山康方生物医药有限公司 |
抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
|
|
WO2020047345A1
(en)
|
2018-08-31 |
2020-03-05 |
Yale University |
Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
|
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
|
TW202024131A
(zh)
|
2018-09-07 |
2020-07-01 |
美商輝瑞大藥廠 |
抗-αvβ8抗體及組合物及其用途
|
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
|
WO2020053654A1
(en)
|
2018-09-12 |
2020-03-19 |
Novartis Ag |
Antiviral pyridopyrazinedione compounds
|
|
SG11202102644XA
(en)
|
2018-09-19 |
2021-04-29 |
Alpine Immune Sciences Inc |
Methods and uses of variant cd80 fusion proteins and related constructs
|
|
WO2020058372A1
(en)
|
2018-09-19 |
2020-03-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
US10815311B2
(en)
|
2018-09-25 |
2020-10-27 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
|
AU2019346645A1
(en)
|
2018-09-27 |
2021-04-29 |
Marengo Therapeutics, Inc. |
CSF1R/CCR2 multispecific antibodies
|
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
|
EP3856782A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
JP2022502385A
(ja)
|
2018-09-29 |
2022-01-11 |
ノバルティス アーゲー |
Ｓｈｐ２の活性を阻害するための化合物の製造方法
|
|
WO2020070053A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
|
WO2020072821A2
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
|
CR20210239A
(es)
|
2018-10-12 |
2021-12-15 |
Xencor Inc |
Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
|
|
BR112021007318A2
(pt)
|
2018-10-17 |
2021-08-31 |
Biolinerx Ltd. |
Tratamento de adenocarcinoma pancreático metastático
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
WO2020092848A2
(en)
|
2018-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
AU2019374103A1
(en)
|
2018-11-01 |
2021-05-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
|
|
US20220001026A1
(en)
|
2018-11-08 |
2022-01-06 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
|
WO2020102375A1
(en)
|
2018-11-14 |
2020-05-22 |
Regeneron Pharmaceuticals, Inc. |
Intralesional administration of pd-1 inhibitors for treating skin cancer
|
|
WO2020099230A1
(en)
|
2018-11-14 |
2020-05-22 |
Bayer Aktiengesellschaft |
Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
|
|
JP2022507606A
(ja)
|
2018-11-16 |
2022-01-18 |
ネオイミューンテック， インコーポレイテッド |
Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
|
|
AU2019381827A1
(en)
|
2018-11-16 |
2021-06-10 |
Juno Therapeutics, Inc. |
Methods of dosing engineered T cells for the treatment of B cell malignancies
|
|
EP3886842A1
(en)
|
2018-11-26 |
2021-10-06 |
Debiopharm International SA |
Combination treatment of hiv infections
|
|
US20220018828A1
(en)
|
2018-11-28 |
2022-01-20 |
Inserm (Institut National De La Santé Et La Recherche Médicale |
Methods and kit for assaying lytic potential of immune effector cells
|
|
MX2021006238A
(es)
|
2018-11-30 |
2021-10-01 |
Juno Therapeutics Inc |
Metodos para tratamiento que usan terapia celular adoptiva.
|
|
WO2020115262A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
|
WO2020127059A1
(en)
|
2018-12-17 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sulconazole as a furin inhibitor
|
|
CA3123511A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP3897853A1
(en)
|
2018-12-20 |
2021-10-27 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
CA3118182A1
(en)
|
2018-12-21 |
2020-06-25 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
|
EP3898697A2
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Antibodies to pmel17 and conjugates thereof
|
|
AU2020208909A1
(en)
|
2019-01-15 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy
|
|
US11116729B2
(en)
|
2019-01-17 |
2021-09-14 |
Georgia Tech Research Corporation |
Drug delivery systems containing oxidized cholesterols
|
|
SG11202107396RA
(en)
|
2019-01-21 |
2021-08-30 |
Sanofi Sa |
Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers
|
|
MA54863A
(fr)
|
2019-01-29 |
2021-12-08 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques du récepteur orphelin-1 de type récepteur à tyrosine kinase (ror1)
|
|
EP3924521A4
(en)
|
2019-02-15 |
2023-03-29 |
IncellDx, Inc. |
BLADDER-ASSOCIATED SPECIMEN ASSAY, IDENTIFICATION AND TREATMENT OF BLADDER-ASSOCIATED NEOPLASIA, AND KITS FOR USE THEREOF
|
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
KR20210129672A
(ko)
|
2019-02-15 |
2021-10-28 |
노파르티스 아게 |
치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
US20220088075A1
(en)
|
2019-02-22 |
2022-03-24 |
The Trustees Of The University Of Pennsylvania |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
MX2021010228A
(es)
|
2019-02-28 |
2021-10-26 |
Regeneron Pharma |
Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel.
|
|
MX2021010560A
(es)
|
2019-03-06 |
2021-11-12 |
Regeneron Pharma |
Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
|
|
MX2021011753A
(es)
|
2019-03-26 |
2022-01-31 |
Univ Michigan Regents |
Degradadores de moleculas peque?as de stat3.
|
|
EP3947403A1
(en)
|
2019-03-29 |
2022-02-09 |
The Regents Of The University Of Michigan |
Stat3 protein degraders
|
|
EA202192695A1
(ru)
*
|
2019-04-02 |
2021-12-23 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Комбинации ингибиторов транскрипции и ингибиторов иммунных контрольных точек для лечения заболевания
|
|
WO2020201362A2
(en)
|
2019-04-02 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
WO2020208060A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
|
US20220220480A1
(en)
|
2019-04-17 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
|
EP3969040A1
(en)
|
2019-05-13 |
2022-03-23 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
|
|
KR20220010525A
(ko)
|
2019-05-20 |
2022-01-25 |
메사추세츠 인스티튜트 오브 테크놀로지 |
보론산 에스테르 전구약물 및 그의 용도
|
|
AU2020281535A1
(en)
|
2019-05-24 |
2022-01-27 |
Merck Patent Gmbh |
Combination therapies using CDK inhibitors
|
|
CN114269715A
(zh)
|
2019-06-12 |
2022-04-01 |
范德比尔特大学 |
作为氨基酸转运抑制剂的二苄基胺
|
|
WO2020252353A1
(en)
|
2019-06-12 |
2020-12-17 |
Vanderbilt University |
Amino acid transport inhibitors and the uses thereof
|
|
EP3986454A1
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
MA56533A
(fr)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Co |
Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1
|
|
CN114127073B
(zh)
|
2019-07-16 |
2024-05-31 |
密歇根大学董事会 |
作为eed抑制剂的咪唑并嘧啶和其用途
|
|
JP2022542450A
(ja)
*
|
2019-08-02 |
2022-10-03 |
康方▲藥▼▲業▼有限公司 |
抗ｃｔｌａ４／抗ｐｄ－１二重特異性抗体及びその使用
|
|
EP4007592A1
(en)
|
2019-08-02 |
2022-06-08 |
LanthioPep B.V. |
Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
|
|
BR112022002406A2
(pt)
|
2019-08-12 |
2022-07-19 |
Purinomia Biotech Inc |
Métodos e composições para promover e potencializar respostas imunes mediadas por célula t através do alvejamento de adcc de células que expressam cd39
|
|
GB201912107D0
(en)
|
2019-08-22 |
2019-10-09 |
Amazentis Sa |
Combination
|
|
WO2021041532A1
(en)
|
2019-08-26 |
2021-03-04 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
|
AU2020336381A1
(en)
|
2019-08-27 |
2022-03-03 |
The Regents Of The University Of Michigan |
Cereblon E3 ligase inhibitors
|
|
KR20220053007A
(ko)
|
2019-08-30 |
2022-04-28 |
아게누스 인코포레이티드 |
항-cd96 항체 및 이의 사용 방법
|
|
KR20220062500A
(ko)
|
2019-09-16 |
2022-05-17 |
서피스 온콜로지, 인크. |
항-cd39 항체 조성물 및 방법
|
|
RS65480B1
(sr)
|
2019-09-18 |
2024-05-31 |
Lamkap Bio Alpha AG |
Bispecifična antitela protiv ceacam5 i cd3
|
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
KR20220064983A
(ko)
|
2019-09-18 |
2022-05-19 |
노파르티스 아게 |
Nkg2d 융합 단백질 및 이의 용도
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
AU2020348849A1
(en)
|
2019-09-19 |
2022-04-07 |
The Regents Of The University Of Michigan |
Spirocyclic androgen receptor protein degraders
|
|
JP2022549495A
(ja)
|
2019-09-25 |
2022-11-25 |
シージェン インコーポレイテッド |
造血器がんの治療のための抗ｃｄ３０ ａｄｃ、抗ｐｄ－１、および化学療法剤の併用
|
|
KR20220066346A
(ko)
|
2019-09-25 |
2022-05-24 |
서피스 온콜로지, 인크. |
항-il-27 항체 및 이의 용도
|
|
AU2020353055B2
(en)
|
2019-09-26 |
2024-03-07 |
Gilead Sciences, Inc. |
Antiviral pyrazolopyridinone compounds
|
|
CA3151322A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
|
WO2021067863A2
(en)
|
2019-10-03 |
2021-04-08 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
|
AU2020389422A1
(en)
*
|
2019-11-20 |
2022-06-02 |
Gi Cell, Inc. |
Medium composition for culturing T cells and method for culturing T cells using same
|
|
MX2022006365A
(es)
|
2019-11-26 |
2022-06-22 |
Novartis Ag |
Receptores de antigeno quimerico cd19 y cd22 y usos de los mismos.
|
|
WO2021108025A1
(en)
|
2019-11-26 |
2021-06-03 |
Massachusetts Institute Of Technology |
Cell-based cancer vaccines and cancer therapies
|
|
GB201917254D0
(en)
|
2019-11-27 |
2020-01-08 |
Adc Therapeutics Sa |
Combination therapy
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
EP3920976B1
(en)
|
2019-12-04 |
2023-07-19 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
|
CA3164124A1
(en)
|
2019-12-09 |
2021-06-17 |
Seagen Inc. |
Combination therapy with liv1-adc and pd-1 antagonist
|
|
CN115175937A
(zh)
|
2019-12-20 |
2022-10-11 |
诺华股份有限公司 |
用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
CN111110655B
(zh)
*
|
2020-01-20 |
2020-12-25 |
山东大学 |
一种纳米复合物及其制备方法和应用
|
|
EP4096698A1
(en)
|
2020-01-28 |
2022-12-07 |
Genentech, Inc. |
Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer
|
|
US20230086099A1
(en)
|
2020-01-30 |
2023-03-23 |
Ona Therapeutics, S.L. |
Combination therapy for treatment of cancer and cancer metastasis
|
|
TW202146452A
(zh)
|
2020-02-28 |
2021-12-16 |
瑞士商諾華公司 |
結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥
|
|
KR20220151195A
(ko)
|
2020-03-06 |
2022-11-14 |
오엔에이 테라퓨틱스 에스.엘. |
항-cd36 항체 및 암을 치료하기 위한 이의 용도
|
|
JP2023518295A
(ja)
|
2020-03-20 |
2023-04-28 |
オルナ セラピューティクス インコーポレイテッド |
環状ｒｎａ組成物及び方法
|
|
US20230159573A1
(en)
|
2020-03-26 |
2023-05-25 |
The Regents Of The University Of Michigan |
Small molecule stat protein degraders
|
|
CA3179800A1
(en)
|
2020-04-10 |
2021-10-14 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
CN116589581A
(zh)
|
2020-05-01 |
2023-08-15 |
恩格姆生物制药公司 |
Ilt结合剂和其使用方法
|
|
IL298019A
(en)
|
2020-05-13 |
2023-01-01 |
Massachusetts Inst Technology |
Compositions of polymeric microdevices and their use in cancer immunotherapy
|
|
KR20230015954A
(ko)
|
2020-05-26 |
2023-01-31 |
리제너론 파마슈티칼스 인코포레이티드 |
Pd-1 억제제의 투여에 의한 자궁경부암의 치료 방법
|
|
CA3184802A1
(en)
|
2020-05-26 |
2021-12-02 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
|
|
EP4157319A1
(en)
|
2020-05-28 |
2023-04-05 |
Modernatx, Inc. |
Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
|
|
US11767353B2
(en)
|
2020-06-05 |
2023-09-26 |
Theraly Fibrosis, Inc. |
Trail compositions with reduced immunogenicity
|
|
IL298473A
(en)
|
2020-06-11 |
2023-01-01 |
Novartis Ag |
zbtb32 inhibitors and uses thereof
|
|
TW202214857A
(zh)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
新型結合核酸分子及其用途
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
WO2022011204A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Small molecule androgen receptor protein degraders
|
|
WO2022011205A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
JP2023540217A
(ja)
|
2020-08-26 |
2023-09-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｐｄ－１阻害剤を投与することによりがんを処置する方法
|
|
EP4204458A1
(en)
|
2020-08-26 |
2023-07-05 |
Marengo Therapeutics, Inc. |
Methods of detecting trbc1 or trbc2
|
|
WO2022049526A1
(en)
|
2020-09-02 |
2022-03-10 |
Pharmabcine Inc. |
Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer
|
|
AU2021337650A1
(en)
|
2020-09-03 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer pain by administering a pd-1 inhibitor
|
|
EP4211148A1
(en)
*
|
2020-09-08 |
2023-07-19 |
Eutilex Co., Ltd. |
Pd-1 polypeptide variants
|
|
EP4217394A1
(en)
|
2020-09-24 |
2023-08-02 |
Merck Sharp & Dohme LLC |
Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
|
|
EP4222171A1
(en)
|
2020-10-02 |
2023-08-09 |
Regeneron Pharmaceuticals, Inc. |
Combination of antibodies for treating cancer with reduced cytokine release syndrome
|
|
JP2023548529A
(ja)
|
2020-11-06 |
2023-11-17 |
ノバルティス アーゲー |
Ｃｄ１９結合分子及びその使用
|
|
WO2022101302A1
(en)
|
2020-11-12 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
|
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
|
US20220168293A1
(en)
|
2020-12-02 |
2022-06-02 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
|
US20240050432A1
(en)
|
2020-12-08 |
2024-02-15 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
|
KR20220082558A
(ko)
|
2020-12-10 |
2022-06-17 |
재단법인 의약바이오컨버젼스연구단 |
면역 증진 활성이 있는 신규 crs 단편 펩타이드 및 이의 용도
|
|
KR20230121772A
(ko)
|
2020-12-18 |
2023-08-21 |
람카프 바이오 베타 엘티디. |
Ceacam5 및 cd47에 대한 이중특이적 항체
|
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
|
|
WO2022165403A1
(en)
|
2021-02-01 |
2022-08-04 |
Yale University |
Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment
|
|
WO2022171121A1
(zh)
|
2021-02-10 |
2022-08-18 |
同润生物医药(上海)有限公司 |
治疗肿瘤的方法和组合
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US20240166647A1
(en)
|
2021-03-03 |
2024-05-23 |
The Regents Of The University Of Michigan |
Cereblon Ligands
|
|
WO2022187419A1
(en)
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
|
JP2024510947A
(ja)
|
2021-03-05 |
2024-03-12 |
レアダルティス、ソシエダッド リミターダ |
三量体ポリペプチドおよびがん治療におけるその使用
|
|
CA3170902A1
(en)
|
2021-03-23 |
2022-09-23 |
Jigar Desai |
Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
|
|
US20240181052A1
(en)
|
2021-03-29 |
2024-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
|
EP4322938A1
(en)
|
2021-04-14 |
2024-02-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
New method to improve nk cells cytotoxicity
|
|
MX2023012277A
(es)
|
2021-04-16 |
2023-12-07 |
Novartis Ag |
Conjugados anticuerpo-fármaco y métodos para fabricar los mismos.
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2022242737A1
(zh)
|
2021-05-21 |
2022-11-24 |
天津立博美华基因科技有限责任公司 |
药物组合及其用途
|
|
AU2022281461A1
(en)
|
2021-05-25 |
2024-01-04 |
Edelweiss Immune Inc |
C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
|
|
CN117396512A
(zh)
|
2021-05-26 |
2024-01-12 |
分子免疫中心 |
治疗组合物用于治疗上皮源性肿瘤患者的用途
|
|
WO2022254337A1
(en)
|
2021-06-01 |
2022-12-08 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
WO2022256538A1
(en)
|
2021-06-03 |
2022-12-08 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
|
|
WO2023280790A1
(en)
|
2021-07-05 |
2023-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
|
EP4373505A1
(en)
|
2021-07-19 |
2024-05-29 |
Regeneron Pharmaceuticals, Inc. |
Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
|
|
KR20240042476A
(ko)
|
2021-07-30 |
2024-04-02 |
오엔에이 테라퓨틱스 에스.엘. |
항-cd36 항체 및 암을 치료하기 위한 이의 용도
|
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
|
WO2023015198A1
(en)
|
2021-08-04 |
2023-02-09 |
Genentech, Inc. |
Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
|
|
CN118043352A
(zh)
|
2021-09-02 |
2024-05-14 |
德国癌症研究中心公共法律基金会 |
副作用减少的抗cecam6抗体
|
|
CN118201914A
(zh)
|
2021-09-08 |
2024-06-14 |
雷多纳治疗公司 |
Papd5和/或papd7抑制剂4-氧代-1,4-二氢喹啉-3-甲酸衍生物
|
|
WO2023057882A1
(en)
|
2021-10-05 |
2023-04-13 |
Pfizer Inc. |
Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
|
|
AU2022377637A1
(en)
|
2021-10-28 |
2024-05-02 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
|
CA3238660A1
(en)
|
2021-11-17 |
2023-05-25 |
Institut National De La Sante Et De La Recherche Medicale |
Universal sarbecovirus vaccines
|
|
CA3240558A1
(en)
|
2021-12-16 |
2023-06-22 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
|
WO2023130081A1
(en)
|
2021-12-30 |
2023-07-06 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
|
WO2023133280A1
(en)
|
2022-01-07 |
2023-07-13 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
CN114432441B
(zh)
*
|
2022-01-11 |
2023-04-25 |
中国人民解放军陆军军医大学第一附属医院 |
一种pd-1修饰的金复合硒化铜纳米粒子及其在介导光热靶向治疗癌症方面的应用
|
|
WO2023154905A1
(en)
|
2022-02-14 |
2023-08-17 |
Gilead Sciences, Inc. |
Antiviral pyrazolopyridinone compounds
|
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|
|
WO2023159102A1
(en)
|
2022-02-17 |
2023-08-24 |
Regeneron Pharmaceuticals, Inc. |
Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
|
|
WO2023161453A1
(en)
|
2022-02-24 |
2023-08-31 |
Amazentis Sa |
Uses of urolithins
|
|
WO2023177772A1
(en)
|
2022-03-17 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
WO2023196988A1
(en)
|
2022-04-07 |
2023-10-12 |
Modernatx, Inc. |
Methods of use of mrnas encoding il-12
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2023224912A1
(en)
|
2022-05-16 |
2023-11-23 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
WO2023230554A1
(en)
|
2022-05-25 |
2023-11-30 |
Pfizer Inc. |
Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
|
|
WO2023242351A1
(en)
|
2022-06-16 |
2023-12-21 |
Lamkap Bio Beta Ag |
Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
|
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
WO2024015803A2
(en)
|
2022-07-11 |
2024-01-18 |
Autonomous Therapeutics, Inc. |
Encrypted rna and methods of its use
|
|
US20240043560A1
(en)
|
2022-08-02 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 Antibodies
|
|
US20240041929A1
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
|
WO2024040264A1
(en)
|
2022-08-19 |
2024-02-22 |
Massachusetts Institute Of Technology |
Compositions and methods for targeting dendritic cell lectins
|
|
WO2024052356A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
|
WO2024076926A1
(en)
|
2022-10-03 |
2024-04-11 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies
|
|
WO2024081736A2
(en)
|
2022-10-11 |
2024-04-18 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
|
WO2024102722A1
(en)
|
2022-11-07 |
2024-05-16 |
Neoimmunetech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|
|
WO2024112867A1
(en)
|
2022-11-23 |
2024-05-30 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods of use thereof for increasing immune responses
|